22 Tex. Admin. Code § 228.2 - Prescription Monitoring Program (PMP)
(a)
APRNs should access and review the prescription monitoring program (PMP)
authorized by Chapter 481, Health and Safety Code, prior to prescribing any
controlled substance for patients being treated for pain.
(b) APRNs must access and review the PMP
before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
unless:
(1) the patient has been diagnosed
with cancer or the patient is receiving hospice care; and
(2) the APRN clearly notes on the
prescription or in the electronic prescription record that the patient was
diagnosed with cancer or is receiving hospice care, as applicable.
(c) An APRN will not be subject to
disciplinary action if the APRN:
(1) makes a
good faith attempt to access and review the PMP prior to prescribing opioids,
benzodiazepines, barbiturates, or carisoprodol, but is unable to access the
information because of circumstances outside the control of the APRN;
and
(2) clearly notes on the
patient's prescription or in the patient's electronic prescription record the
APRN's attempt to access and review the PMP and the circumstances that
prevented the APRN from being able to do so.
(d) Documentation that the review of the PMP
occurred and rationale for prescribing a controlled substance must be included
in the patient's medical record.
(e) This section takes effect September 1,
2019.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.